v3.26.1
Condensed Statements of Changes in Shareholders' Deficit - USD ($)
Common Stock [Member]
Archimedes Tech SPAC Partners II Co [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Archimedes Tech SPAC Partners II Co [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Archimedes Tech SPAC Partners II Co [Member]
Retained Earnings [Member]
Archimedes Tech SPAC Partners II Co [Member]
Total
Balance (in shares) at Dec. 31, 2024 5,750,000              
Balance at Dec. 31, 2024 $ 575   $ 24,425   $ (78,700)   $ (53,700)  
Balance (in shares) at Jun. 06, 2024 0              
Balance at Jun. 06, 2024 $ 0   0   0   0  
Net income [1] $ 0   0   (78,700)   (78,700)  
Sale of 840,0000 private placement units (in shares) 5,750,000              
Sale of 840,0000 private placement units $ 575   24,425   0   25,000  
Balance (in shares) at Dec. 31, 2024 5,750,000              
Balance at Dec. 31, 2024 $ 575   24,425   (78,700)   (53,700)  
Accretion of ordinary shares subject to possible redemption amount $ 0   (10,032,147)   (7,207,063)   (17,239,210)  
Net income         1,159,223   $ 1,159,223  
Sale of 840,0000 private placement units (in shares) 840,000           8,400,000  
Sale of 840,0000 private placement units $ 84   8,399,916       $ 8,400,000  
Fair value of Public Warrants at issuance     1,725,000       1,725,000  
Allocated value of transaction costs to warrants and private placement units $ 0   (117,194)   0   (117,194)  
Balance (in shares) at Mar. 31, 2025 6,590,000              
Balance at Mar. 31, 2025 $ (659)   0   6,126,540   6,125,881  
Balance (in shares) at Dec. 31, 2024 5,750,000              
Balance at Dec. 31, 2024 $ 575   24,425   (78,700)   (53,700)  
Accretion of ordinary shares subject to possible redemption amount 0   (10,032,147)   (14,612,148)   (24,644,295)  
Net income $ 0 [1]   0   7,986,738   $ 7,986,738  
Sale of 840,0000 private placement units (in shares) 840,000           8,400,000  
Sale of 840,0000 private placement units $ 84   8,399,916   0   $ 8,400,000  
Fair value of Public Warrants at issuance 0   1,725,000   0   1,725,000  
Allocated value of transaction costs to warrants and private placement units $ 0 [1]   (117,194)   0   (117,194)  
Balance (in shares) at Dec. 31, 2025 6,590,000 100           100
Balance at Dec. 31, 2025 $ 659   0 $ 10 (6,704,110) $ (659) (6,703,451) $ (659)
Balance (in shares) at Dec. 03, 2025   0            
Balance at Dec. 03, 2025   $ 0   0   0   0
Net income           (659)   $ (659)
Sale of 840,0000 private placement units (in shares)   100            
Sale of 840,0000 private placement units       10        
Balance (in shares) at Dec. 31, 2025 6,590,000 100           100
Balance at Dec. 31, 2025 $ 659   $ 0 10 (6,704,110) (659) (6,703,451) $ (659)
Accretion of ordinary shares subject to possible redemption amount         (2,141,962)   (2,141,962)  
Net income         1,704,803 (37,269) 1,704,803 $ (37,269)
Balance (in shares) at Mar. 31, 2026 6,590,000             100
Balance at Mar. 31, 2026 $ 659     $ 10 $ (7,141,269) $ (37,928) $ (7,140,610) $ (37,928)
[1] As of December 31, 2024, included an aggregate of up to 750,000 ordinary shares that were subject to forfeiture depending on the extent to which the underwriters’ over-allotment option was exercised (see Note 5). On February 12, 2025, the Company consummated its Initial Public Offering and sold 23,000,000 Units, including 3,000,000 Units sold pursuant to the full exercise of the underwriters’ option to purchase additional units to cover the over-allotment; as a result, the 750,000 ordinary shares were no longer subject to forfeiture.